【chicco replacement cover for high chair】Aligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer
SOUTH SAN FRANCISCO,chicco replacement cover for high chair Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted, antiviral therapies including chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, today announced the appointment of Lesley Ann Calhoun as chief financial officer. Ms. Calhoun will serve as a member of the Aligos leadership team and will report to Aligos’ chief executive officer, Lawrence Blatt, Ph.D., MBA.
Ms. Calhoun is an experienced finance executive with 17 years in the biopharma industry as well as an earlier career in U.S. and multinational technology companies and public accounting. She brings broad experience in both public and pre-IPO companies and in driving financial vision, direction, guidance and compliance to support and advise on operations for companies. She has had a successful career in transforming companies from private, pre-IPO stages to publicly traded business driven, commercial operating companies.
“With Ms. Calhoun’s significant financial and business operations experience, we are pleased to welcome her to the team as we move our lead chronic hepatitis B candidates toward clinical development,” said Dr. Blatt. “She has led numerous companies through major periods of growth and finance planning activities, and I look forward to partnering with Lesley on executing our initiatives with a clear goal of developing a functional cure for patients with chronic hepatitis B.”
Prior to joining the Aligos team, Ms. Calhoun most recently served as senior vice president of finance & administration and chief accounting officer at Global Blood Therapeutics, where she was responsible for the finance, accounting and administrative functions aimed at supporting the companies’ transition from clinical stage to a publicly traded, commercial environment and was part of the company’s successful regulatory approval and commercial launch of Oxbryta
®
for the treatment of sickle cell disease. Previously, Ms. Calhoun served as vice president of finance at Hyperion Therapeutics Inc., a commercial stage biopharmaceutical company focused on orphan diseases. During her time there, she was instrumental in building the company’s finance infrastructure, which led to the successful commercialization of RAVICTI
®
for the treatment of urea cycle disorders. Prior to her time at Hyperion, she served as senior director of finance/corporate controller at Theravance, Inc., where she supported the company’s CFO and was responsible for all corporate and regulatory accounting reporting, serving as a key player in the company’s financial vision and direction.
Story continues
Ms. Calhoun has also held roles of increasing financial responsibility at Cell Genesys, Inc., Snap Appliances, Inc., Inktomi Corporation and Silicon Graphics, Inc. and was a member of the audit practice of Deloitte & Touche LLP.
Ms. Calhoun stated, “I am honored to join the Aligos team sitting parallel to veteran experts with years of drug research and development experience, and I look forward to joining them in driving Aligos’ future financial, strategic and operational capabilities. With a diversified asset portfolio in chronic hepatitis B backed by elite management and scientific teams, the company is well positioned to advance toward the clinic.”
Ms. Calhoun received her Bachelor of Science in Business Administration from San Francisco State University and is a Certified Public Accountant (inactive).
About Aligos
Aligos Therapeutics, Inc. is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases. Aligos is focused on the development of targeted, antiviral therapies including chronic hepatitis B (CHB) and COVID-19 as well as leveraging expertise in liver diseases to create targeted therapeutics for NASH, which collectively affect hundreds of millions of people across the world. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of best-in-class molecules.
Please visit www.aligos.com for more information.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
View comments
-
Bitcoin falls below 8,000 ahead of what is expected to be a rough day for U.S. stocksIs It Smart To Buy Shoe Carnival, Inc. (NASDAQ:SCVL) Before It Goes Ex-Dividend?Excerpts of high court campaign finance opinionsUniversal Stainless to Present at Cowen and Company 40th Annual Aerospace/Defense & Industrials Conference on February 7thMasco Banks on Repair & Remodeling Business Amid High CostsMorning News Call - Canada, January 2BioNTech founders warn of vaccine supply gaps - SpiegelThe State of Medical Marijuana Is at a Crossroads in FloridaBuying a House? 4 Things to Take Off Your Must-Have List NowA Look At The Fair Value Of Canadian National Railway Company (TSE:CNR)
下一篇:Home of the Week: Bird Streets aerie offers a showcase of design
- ·No matter how long you've been at this, your small business is now a startup
- ·BRIEF-China Jialing Industrial Says It Sold 3,112 Motorcycles In Jan
- ·Is Elmos Semiconductor AG’s (ETR:ELG) 13% ROE Strong Compared To Its Industry?
- ·Blake Nordstrom, co-president of Nordstrom, dies at age 58 after fight with cancer
- ·Exclusive: StanChart says CEO Winters will stay to execute current strategy
- ·Shares in Brazilian asset manager Tarpon up 8.8 pct at opening
- ·What Percentage Of Vidrala, S.A. (BME:VID) Shares Do Insiders Own?
- ·There's A Lot To Like About Finolex Cables Limited's (NSE:FINCABLES) Upcoming 1.2% Dividend
- ·Will Fastly Continue to Surge Higher?
- ·January ETF Asset Report
- ·India unveils budget aimed at wooing countryside before election
- ·North Korea leader Kim to leave Hanoi around noon on Saturday - source
- ·Freedom Trail and Black Heritage Trail Bring History Into Homes Near and Far
- ·At €3.65, Is It Time To Put Derichebourg (EPA:DBG) On Your Watch List?
- ·EMERGING MARKETS-Brazil's real firms against dollar, bucking Latam trend
- ·Are N. Leventeris S.A.’s (ATH:LEBEK) Interest Costs Too High?
- ·CLNY Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Colony Capital, Inc. and Encourages Investors to Contact the Firm
- ·Our Take On XPD Soccer Gear Group Limited’s (ASX:XPD) CEO Salary
- ·CBS Soars to a New 52-Week High
- ·Is CyberOptics Corporation’s (NASDAQ:CYBE) Balance Sheet Strong Enough To Weather A Storm?
- ·SEC delays decision on tZERO’s proposed security token exchange
- ·FloBeds Announces 25th Anniversary of Delivering Dreams via Internet
- ·'Undefeated and Unindicted' Trey Gowdy Shares Plans for Nelson Mullins Role
- ·EU and UK markets watchdogs agree pacts in case of no deal Brexit
- ·Should Value Investors Buy Avis Budget Group (CAR) Stock?
- ·Top Picks 2019- Twilio TWLO
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·Nexon founder to sell controlling stake in gaming co's holding firm - Korea Economic Daily
- ·BRIEF-GCL New Energy Holdings Announces Disposal Of Certain Units
- ·Mark Goldfinger Examines the Benefits of a Hybrid Investment Strategy
- ·Earnings Preview: Novanta (NOVT) Q3 Earnings Expected to Decline
- ·Mark Goldfinger Examines the Benefits of a Hybrid Investment Strategy
- ·Read This Before Considering Vitasoy International Holdings Limited (HKG:345) For Its Upcoming HK$0.038 Dividend
- ·7 Connecticut Attorneys Disciplined, Grievance Committee Reports
- ·Manganese X Receives Eligibility for DTC Trading in the U.S.
- ·James Sworn In as New York Attorney General